Aspen Neuroscience Shares Promising Results from ASPIRO Phase 1/2a Clinical Trial of Parkinson's Cell Therapy

Promising Advancements in Parkinson's Disease Treatment

Aspen Neuroscience has made headlines following its recent announcement regarding the ASPIRO Phase 1/2a clinical trial results for its revolutionary personalized cell therapy aimed at treating Parkinson's Disease (PD). The clinical trial involved the administration of ANPD001, a type of autologous dopaminergic neuronal precursor cell (DANPC) therapy, which has shown early positive outcomes for patients suffering from moderate to advanced stages of the disease.

Overview of the ASPIRO Phase 1/2a Clinical Trial

On May 7, 2025, Aspen Neuroscience published six-month data from three initial participants involved in the ASPIRO trial, which stands for Autologous-derived Study of a Parkinson's Investigational Regenerative therapy in an Open-label trial. This therapy aims to replace lost dopaminergic neurons in individuals with Parkinson’s disease, utilizing their own cells to minimize safety risks associated with immunosuppression. The results will also be presented at the International Association of Parkinsonism and Related Disorders (IAPRD) conference in New York City.

According to Dr. Avram Fraint, the Medical Director of Aspen Neuroscience, the data so far indicate that ANPD001 is both safe and well-tolerated, with no significant safety issues arising during the trial. The encouraging results observed among the participants showcase both improvements in clinician-reported outcomes and positive feedback from the patients themselves.

Key Findings from the Trial

Among the notable findings, patients who received the therapy reported a significant average improvement of 45% in physician-reported MDS-Unified Parkinson disease Part III score. Furthermore, patients noted a reduction in 'off' time, where symptoms are more pronounced, alongside a marked 71% improvement in the MDS-UPDRS Part II scores, which reflect the patients' self-assessments of their daily living activities affected by PD. The trials also highlighted a decrease of two hours in